Foundayo vs Zepbound

Foundayo (orforglipron) and Zepbound (tirzepatide) are both FDA-approved for chronic weight management in adults with obesity or overweight with comorbidities — and both are made by Eli Lilly. This is a genuine head-to-head comparison between two branded obesity medications from the same manufacturer. The drugs differ sharply in mechanism, route of administration, and the magnitude of weight loss demonstrated in pivotal trials. For patients deciding between them, the central trade-off is oral-pill convenience against a nearly 2x weight-loss advantage for the weekly injection.

Both Carry the Same Weight-Management Indication

Foundayo received FDA approval on April 1, 2026, for chronic weight management in adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbid condition, as an adjunct to a reduced-calorie diet and increased physical activity. Zepbound received the same class of chronic-weight-management approval in November 2023 under virtually identical BMI criteria. In December 2024, the FDA additionally approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity — an indication Foundayo does not hold. For weight management alone, the indications are parallel.

Different Mechanisms Behind the Same Receptor Family

Foundayo is orforglipron, a non-peptide small-molecule GLP-1 receptor agonist. It activates the GLP-1 receptor to suppress appetite, slow gastric emptying, and stimulate insulin secretion in a glucose-dependent manner. As a small molecule, it is orally bioavailable without the need for injection or food-window restrictions. Zepbound is tirzepatide, a synthetic peptide that acts as a dual agonist at both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. The added GIP receptor engagement amplifies fat-mass reduction through mechanisms beyond single GLP-1 agonism. Zepbound must be injected subcutaneously because peptides are degraded in the gastrointestinal tract before reaching the bloodstream.

Weight Loss Efficacy in Pivotal Trials

The ATTAIN-1 trial (72 weeks) demonstrated that Foundayo 36 mg daily produced a mean weight reduction of approximately 12.4 percent of baseline body weight versus placebo in adults with obesity. Roughly 59.6 percent of participants on the highest dose achieved at least 10 percent body weight reduction, and 39.6 percent achieved at least 15 percent.

The SURMOUNT-1 trial (72 weeks) demonstrated that Zepbound 15 mg weekly produced a mean weight reduction of approximately 22.5 percent of baseline body weight (25.3 kg absolute) versus placebo in adults without diabetes. Approximately 63 percent of treated patients lost 20 percent or more of their starting body weight.

These are separate placebo-controlled trials with different populations, so direct cross-trial comparison requires caution. The consistent pattern is that Zepbound's dual GIP and GLP-1 mechanism, combined with its injectable delivery achieving higher systemic drug exposure, produces approximately 80 percent greater mean weight loss than Foundayo's oral GLP-1 mono-agonist approach.

Route of Administration

Foundayo is taken as a once-daily oral tablet, at any time of day, with or without food. No injection technique, no pen storage, no needle disposal. For the estimated one in four adults with clinically significant needle aversion, Foundayo removes the single largest barrier to starting a GLP-1 weight-management drug. It also avoids the empty-stomach fasting protocol required by Rybelsus, the only other oral GLP-1 on the U.S. market.

Zepbound is a once-weekly subcutaneous injection delivered via prefilled autoinjector pen or single-dose vial into the abdomen, thigh, or upper arm. The weekly schedule means 52 administrations per year compared to 365 for a daily tablet. Patients comfortable with injections often find the weekly cadence easy to maintain.

Zepbound's Additional OSA Indication

Zepbound is the only FDA-approved medication for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial. For patients who carry both an obesity diagnosis and confirmed moderate-to-severe OSA, Zepbound covers both conditions under a single labeled indication, which can simplify prescribing and may support a stronger insurance authorization argument. Foundayo has no OSA data and no OSA indication.

Side Effect Profiles

Both drugs produce the GLP-1 class gastrointestinal profile: nausea, diarrhea, vomiting, and constipation, predominantly mild to moderate and most prominent during dose escalation. ATTAIN-1 reported nausea in roughly 21 to 27 percent of Foundayo-treated patients; SURMOUNT-1 reported nausea in 24 to 33 percent on Zepbound at maintenance doses. The gradient follows efficacy — the drug that achieves greater metabolic effect also generates somewhat more GI burden during escalation. Both drugs carry an FDA boxed warning for thyroid C-cell tumors based on rodent data, and both are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or MEN 2. Zepbound can cause injection-site reactions in a minority of patients; Foundayo does not. Hair loss from rapid weight reduction is reported with both.

Dosing and Titration

Foundayo starts at 3 mg once daily and escalates through 6, 12, 24, and up to 36 mg at 4-week intervals based on tolerability. Zepbound starts at 2.5 mg once weekly and escalates through 5, 7.5, 10, 12.5, and up to 15 mg at 4-week intervals. Both drugs require similar titration patience — roughly 4 to 6 months to reach the highest maintenance doses.

Cost, Coverage, and Access

Neither drug has a generic alternative. Zepbound has been available since late 2023 and Eli Lilly offers tirzepatide in single-dose vials through LillyDirect at self-pay prices of approximately $349 to $699 per month depending on dose and supply option, substantially below the autoinjector pen list price. Foundayo is a new market entrant as of April 2026, with commercial insurance formulary coverage still developing and early Lilly savings cards available to eligible commercially insured patients. Medicare Part D excludes both drugs for weight loss alone under current federal law. Prior authorization is standard for both.

Choosing Between Foundayo and Zepbound

For patients seeking maximum published weight loss: Zepbound's dual mechanism and 22.5 percent mean reduction from SURMOUNT-1 represent the strongest obesity-pharmacotherapy evidence currently available from a once-weekly injectable. For patients with needle aversion, oral medication preference, or injection logistics barriers: Foundayo's 12.4 percent weight loss is meaningful and clinically significant — comparable to early semaglutide data — and is the only modern GLP-1 obesity drug that arrives as a simple daily tablet. For patients with obesity plus moderate-to-severe obstructive sleep apnea: Zepbound's labeled OSA indication makes it the clearer clinical choice. For patients with both type 2 diabetes and obesity, see our comparison of Mounjaro vs Zepbound — combining Foundayo with Zepbound is not a supported clinical strategy.

This article is for informational purposes only and does not constitute medical advice. Prescribing decisions should be made between a patient and their healthcare provider based on the most current FDA prescribing information, individual clinical history, and insurance coverage.